Topic: chronic lymphocytic leukemia
Just a year after approval, AZ’s Calquence is giving Imbruvica a run for its money in MCL. But the British drugmaker doesn’t want to stop there.
Johnson & Johnson and AbbVie’s Imbruvica already competes in previously untreated CLL. But the partners are looking to own it.
AbbVie and Roche’s Venclexta is leaving familiar territory with its latest nod. And to establish itself on its new turf, it’ll have to duke it out with some Big Pharma rivals.
AbbVie and Roche aim to drive further into the chronic lymphocytic leukemia market, and they’re pairing their newer drugs to do it.
The Institut Pasteur spinoff hopes its anti-telomerase cancer vaccine could be useful in immuno-oncology combo therapies.
AbbVie is counting on oncology med Venclexta to drive serious growth, especially as biosimilars to top seller Humira advance. But England has other plans.
AbbVie and Roche just nabbed an FDA approval that spares relapsed leukemia patients chemotherapy—and could be key to $3B in peak sales.
AbbVie seeks to expand use of Imbruvica among previously untreated CLL patients. And it now has some new data that should help it do that.